Assembly Biosciences ASMB Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by Assembly Biosciences in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: Assembly Biosciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Assembly Biosciences's net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Assembly Biosciences's net unrealized gains (losses) on securities still held?
- Assembly Biosciences (ASMB) reported net unrealized gains (losses) on securities still held of -$327K in Q1 2026.
- How has Assembly Biosciences's net unrealized gains (losses) on securities still held changed year-over-year?
- Assembly Biosciences's net unrealized gains (losses) on securities still held decreased by 678.6% year-over-year, from -$42K to -$327K.
- What is the long-term trend for Assembly Biosciences's net unrealized gains (losses) on securities still held?
- Over 3 years (2021 to 2025), Assembly Biosciences's net unrealized gains (losses) on securities still held has grown at a 4.5% compound annual growth rate (CAGR), from -$149K to $170K.
- What does net unrealized gains (losses) on securities still held mean?
- This metric represents the change in the fair value of investment securities held by the company that have not yet been sold. It captures unrealized gains or losses that are excluded from net income but are recognized as part of other comprehensive income. Monitoring this figure helps investors understand the volatility and performance of the company's investment portfolio outside of core operational activities.